#Germany #Kidney Care #Bad Homburg #Fresenius Medical #Hemodiafiltration

Fresenius Medical Care Releases Study on Hemodiafiltration

Fresenius Medical Care (FME), the preeminent global provider of kidney care services and products, has made headlines with the publication of a substantial multinational study showcasing the benefits of high-volume hemodiafiltration (HDF). This study, published in the Journal of the American Society of Nephrology (JASN), presents real-world evidence emphasizing HDF's potential to reduce mortality rates when compared to traditional high-flux hemodialysis.

The study analyzed data from nearly 20,000 dialysis patients from eight European countries, marking it as one of the largest investigations on this topic. The findings revealed that patients undergoing HDF experienced a remarkable 28% lower risk of all-cause mortality compared to those receiving conventional dialysis treatments. For patients with higher convection volumes exceeding 23 liters per session, this risk reduction escalated to an impressive 33%.

Importance of the Findings

The implications of this study are profound for kidney care, as Fresenius Medical Care’s CEO, Helen Giza, pointed out. With an estimated 850 million individuals worldwide suffering from kidney diseases, the urgency for innovative treatment methods is critical. The data underscores the necessity of expanding access to high-volume hemodiafiltration across various regions, particularly in the United States, where Fresenius is actively working to enhance treatment methodologies.

The study used a sophisticated target trial emulation design to compare patient outcomes effectively. This method allows researchers to mimic a randomized clinical trial while evaluating real-world clinical data, thereby strengthening the reliability of the findings. The results affirm that not only is HDF a feasible alternative, but it may also offer significant survival benefits for patients grappling with kidney failure.

Collaborative Efforts in Research

This extensive study highlights the collaborative work of experts in the nephrology field, including renowned figures such as Professors Giovanni Strippoli and Bernard Canaud. Their expertise, coupled with advanced statistical analyses led by Dr. Giovanni Tripepi, lends credence to the findings and signifies a milestone in kidney research.

The release of this study aligns well with previous research, including the EU-funded CONVINCE trial, which further validates the safety and efficacy of high-volume hemodiafiltration in improving patient outcomes. Fresenius Medical Care has been a front-runner in developing this technique over the past two decades, efficiently removing a broader spectrum of toxins from the blood, which may contribute to better health outcomes overall.

Future Prospects for Kidney Care

The advancement in kidney treatment methods is essential as kidney disease becomes a growing health crisis driven by soaring rates of diabetes and hypertension. High-volume hemodiafiltration not only enhances the quality of life for many but also represents a progressive step towards improving longevity among those affected.

Fresenius Medical Care's commitment to ongoing research and innovation is evident in its BEACON-US initiative, which aims to gather U.S.-specific data on the patient experience and clinical outcomes associated with HDF. This initiative reflects the company's dedication to adaptively meeting the needs of patients while striving to transform dialysis care on a global scale.

As kidney health continues to be a significant public health concern, the findings from this study serve as a clarion call for further innovation and expanded access to advanced therapeutic modalities like high-volume hemodiafiltration. Fresenius Medical Care remains steadfast in its goal to enhance kidney care for millions of individuals worldwide.